Telix Pharmaceuticals Limited (TLX.AX)

14,80 -0,65 (-4,21%) Börsenschluss: 04:10PM AEST

Telix Pharmaceuticals Limited

55 Flemington Road
Suite 401
North Melbourne, VIC 3051
Australia
61 3 3093 3897
https://telixpharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Darren Smith B.Bus., FCPA, M.B.A.	Group Chief Financial Officer	571,17k	N/A	1965
Dr. Andreas Kluge M.D., Ph.D.	Chief Medical Advisor & Non-Executive Director	43k	N/A	N/A
Mr. Richard Valeix M.B.A.	Group Chief Commercial Officer	638,49k	N/A	N/A
Mr. Darren Patti	Group Chief Operating Officer	N/A	N/A	N/A
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab)	Chief Scientist	141,76k	N/A	N/A
Mr. Craig Ulrick	Chief Information Officer	N/A	N/A	N/A
Ms. Kyahn Williamson B.A.	Senior Vice President of Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C.	Senior VP of Global Governance, Risk & Compliance	N/A	N/A	N/A
Ms. Lena Moran-Adams L.L.B.	Group General Counsel	N/A	N/A	N/A
Thomas Fromm	Vice President of Sales	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in AUD.

Beschreibung

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Corporate Governance

Telix Pharmaceuticals Limiteds ISS Governance QualityScore, Stand 1. Mai 2024, lautet 5. Die grundlegenden Scores sind Audit: 3, Vorstand: 6, Shareholderrechte: 7, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.